| Literature DB >> 29374228 |
Lotte Smolders1, Ronald P Mensink1, Mark V Boekschoten2, Rogier J J de Ridder3, Jogchum Plat4.
Abstract
Increasing apoA-I synthesis may improve HDL functionality and lower CVD risk. As theobromine and fat increase fasting apoA-I concentrations, and the intestine is involved in apoA-I production, the acute effects of both were studied on duodenal gene transcription to better understand underlying mechanisms. In this crossover study, 8 healthy men received once a low fat (LF) meal, a LF meal plus theobromine (850 mg), or a high fat (HF) meal. Five hours after meal intake duodenal biopsies were taken for microarray analysis. Theobromine and HF consumption did not change duodenal apoA-I expression. Theobromine did not change gene expression related to lipid and cholesterol metabolism, whereas those related to glycogen/glucose breakdown were downregulated. HF consumption increased gene expression related to lipid and cholesterol uptake and transport, and to glucose storage, while it decreased those related to glucose uptake. Furthermore, genes related to inflammation were upregulated, but inflammation markers in plasma were not changed. In healthy men, acute theobromine and fat consumption did not change duodenal apoA-I mRNA, but inhibited expression of genes related to glucose metabolism. Furthermore, HF intake activated in the duodenum expression of genes related to lipid and cholesterol metabolism and to inflammation.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29374228 PMCID: PMC5785967 DOI: 10.1038/s41598-018-20068-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of the participants who completed the study1.
| Mean ± SD | |
|---|---|
| Age (years) | 38 ± 15 |
| BMI (kg/m2) | 24.3 ± 2.0 |
| Serum total cholesterol (mmol/L) | 5.2 ± 0.9 |
| Plasma glucose (mmol/L) | 5.1 ± 0.3 |
| Systolic blood pressure (mmHg) | 130 ± 18 |
| Diastolic blood pressure (mmHg) | 79 ± 14 |
1Values are mean ± SD. n = 8.
Figure 1Significantly different pathways after adding 850 mg of theobromine (TB) to the low-fat/high-carbohydrate (LF) diet. Dotted bars are pathways involved in the immune system, lined bars are pathways involved in cholesterol, lipid or glucose metabolism (n = 8).
Inhibited or activated upstream regulators after adding 850 mg of theobromine (TB) to a low-fat/high-carbohydrate (LF) meal or after comparing high-fat/low-carbohydrate (HF) with LF consumption functioning in lipid, cholesterol or glucose metabolism or the immune system (n = 8).
| Upstream regulator | Activation Z-score | Function (gene card ref) | Comparison |
|---|---|---|---|
| Ins1 | −3.02 | Decreases blood glucose | LF-TB vs. LF |
| Insulin | −2.08 | Decreases blood glucose | LF-TB vs. LF |
| INS | −1.95 | Decreases blood glucose | LF-TB vs. LF |
| INSIG2 | −1.95 | Feedback control of cholesterol synthesis | HF vs. LF |
| APOE | −1.73 | Main lipoprotein on chylomicrons | HF vs. LF |
| ACOX1 | −1.63 | Fatty acid β-oxidation pathway | HF vs. LF |
| SREBF2 | 1.93 | Lipid homeostasis | HF vs. LF |
| PPARα | 1.97 | Transcription factor in lipid and cholesterol metabolism | HF vs. LF |
| FABP2 | 2.00 | Uptake and transport of long chain fatty acids involved in TAG-rich lipoprotein synthesis | HF vs. LF |
| SREBF1 | 2.27 | Transcription factor which regulates lipid homeostasis | HF vs. LF |
| GCG | −2.42 | Proprotein for glucagon | HF vs. LF |
| GCK | −1.98 | Enzyme functioning in glucose utilization | HF vs. LF |
| Gsk3 | 1.98 | Glycogen synthesis | HF vs. LF |
| TNFSF12 | 1.65 | Activation of NFκB, inducer of proinflammatory cytokines | HF vs. LF |
| IL12 | 1.90 | Proinflammatory cytokine | HF vs. LF |
| IL2 | 1.92 | Proinflammatory cytokine | HF vs. LF |
| CD5 | 1.98 | Receptor in the regulation of T-lymphocyte proliferation | HF vs. LF |
| CCL5 | 1.98 | Chemoattractant for monocytes, T-lymphocytes, eosinophils | HF vs. LF |
| TNF | 1.99 | Survival, proliferation and differentiation of monocytes and macrophages | HF vs. LF |
| RELA | 2.02 | Subunit NFκB | HF vs. LF |
| MYD88 | 2.24 | Innate immune response | HF vs. LF |
| IL1A | 2.31 | Proinflammatory cytokine | HF vs. LF |
| TNFSF11 | 2.73 | T-lymphocyte dependent immune response | HF vs. LF |
| IL1B | 2.82 | Proinflammatory cytokine | HF vs. LF |
Significantly inhibited or activated gene sets after adding 850 mg of theobromine (TB) to a low-fat/high-carbohydrate (LF) meal or after comparing high-fat/low-carbohydrate (HF) with LF meal consumption functioning in lipid, cholesterol or glucose metabolism or the immune system (n = 8).
| Name gene set | NES | FDR q-val | Comparison |
|---|---|---|---|
| Glucose metabolism | −1.96 | 0.137 | LF-TB vs. LF |
| Regulation of beta cell development | 1.96 | 0.119 | LF-TB vs. LF |
| Fatty acid beta oxidation | 2.09 | 0.025 | HF vs. LF |
| Regulation of lipid metabolism by PPARα | 1.93 | 0.057 | HF vs. LF |
| PPARα activates gene expression | 1.92 | 0.058 | HF vs. LF |
| Mitochondrial long chain fatty acid β oxidation | 1.88 | 0.075 | HF vs. LF |
| TAG synthesis | 1.82 | 0.106 | HF vs. LF |
| Regulation of lipid metabolism by PPARα | 1.81 | 0.104 | HF vs. LF |
| PPARα signaling pathway | 1.80 | 0.104 | HF vs. LF |
| PPARα targets | 1.80 | 0.101 | HF vs. LF |
| Statin pathway | 1.67 | 0.144 | HF vs. LF |
| SREBP signaling | 1.62 | 0.159 | HF vs. LF |
| Lipid digestion, mobilization and transport | 1.60 | 0.171 | HF vs. LF |
| Fatty acid TAG and ketone body metabolism | 1.60 | 0.167 | HF vs. LF |
| Lipid digestion, mobilization and transport | 1.56 | 0.184 | HF vs. LF |
| Metabolism of steroid hormones and Vit D | 1.58 | 0.175 | HF vs. LF |
| Steroid hormones | 1.57 | 0.178 | HF vs. LF |
| Regulation of cholesterol synthesis by SREBP SREBF | 1.56 | 0.181 | HF vs. LF |
| Lipid digestion, mobilization and transport | 1.55 | 0.183 | HF vs. LF |
| Cholesterol biosynthesis | 1.53 | 0.199 | HF vs. LF |
| Glucose metabolism | −2.29 | 0.001 | HF vs. LF |
| Metabolism of carbohydrates | −2.17 | 0.006 | HF vs. LF |
| Gluconeogenesis | −1.84 | 0.074 | HF vs. LF |
| Hexose transport | −1.83 | 0.073 | HF vs. LF |
| Carbohydrates digestion and absorption | −1.83 | 0.070 | HF vs. LF |
| Glycogen metabolism | −1.78 | 0.064 | HF vs. LF |
| Starch and sucrose metabolism | −1.77 | 0.058 | HF vs. LF |
| Hexose transport | −1.67 | 0.088 | HF vs. LF |
| Pancreatic secretion | −1.61 | 0.129 | HF vs. LF |
| Insulin signalling pathway | −1.59 | 0.136 | HF vs. LF |
| Glycolysis and gluconeogenesis | −1.47 | 0.193 | HF vs. LF |
| Type II diabetes mellitus | −1.47 | 0.196 | HF vs. LF |
| Glycogen storage diseases | −1.46 | 0.198 | HF vs. LF |
| Glucose transport | −1.45 | 0.196 | HF vs. LF |
| Chemokine receptors bind chemokines | 2.08 | 0.020 | HF vs. LF |
| Cell adhesion molecules CAMS | 1.82 | 0.113 | HF vs. LF |
| Cytokine cytokine receptor interaction | 1.82 | 0.110 | HF vs. LF |
| Cytokine and inflammatory response | 1.80 | 0.103 | HF vs. LF |
| Intestinal immune network for IGA production | 1.79 | 0.106 | HF vs. LF |
| RIP mediated NFκB activation via ZBP1 | 1.78 | 0.106 | HF vs. LF |
| ZBP1 DAI mediated induction of type I IFNS | 1.78 | 0.101 | HF vs. LF |
| IL1R pathway | 1.78 | 0.089 | HF vs. LF |
| Rheumatoid arthritis | 1.77 | 0.101 | HF vs. LF |
| NKT pathway | 1.74 | 0.110 | HF vs. LF |
| TNF signaling pathway | 1.73 | 0.112 | HF vs. LF |
| Staphylococcus aureus infection | 1.71 | 0.126 | HF vs. LF |
| NFκB signaling pathway | 1.65 | 0.176 | HF vs. LF |
| TOPB1 pathway | 1.60 | 0.168 | HF vs. LF |
| NTHI pathway | 1.59 | 0.173 | HF vs. LF |
| Inflammatory response pathway | 1.59 | 0.167 | HF vs. LF |
| TNFR2 pathway | 1.57 | 0.180 | HF vs. LF |
| Human complement system | 1.55 | 0.184 | HF vs. LF |
Figure 2Significantly different pathways comparing a high-fat/low-carbohydrate (HF) with a low-fat/high-carbohydrate (LF) diet. Dotted bars are pathways involved in the immune system, lined bars are pathways involved in cholesterol, lipid or glucose metabolism (n = 8).
Figure 3Heatmap of the of the TNF signaling pathway from the GSEA results after the consumption of an acute high-fat/low carbohydrate (HF) vs. low-fat/high-carbohydrate (LF) meal (n = 8).
Figure 4Change in (A), interleukin 6 (IL-6) (B), interleukin 8 (IL-8) (C), tumor necrosis factor alpha (TNF-α) (D), serum amyloid A (SAA) (E), monocyte chemoattractant protein-1 (MCP-1) (F), macrophage inflammatory protein 1 a (MIP-1a) (G), high sensitive C-reactive protein (CRP) (H), vascular cell adhesion protein (VCAM) and (I), intercellular adhesion molecule (ICAM) after acute low-fat/high-carbohydrate (LF, black line, squares) and acute high-fat/low carbohydrate (HF, dotted line, triangles) meal consumption1. 1Values are mean ± SD. n = 8.
Figure 5Change in intestinal fatty acid-binding protein (IFABP) after acute low-fat/high-carbohydrate (LF, black line, squares) and acute high-fat/low-carbohydrate (HF, dotted line, triangles) meal consumption. 1Values are mean ± SD. n = 8.
Nutrient composition of the low-fat/high-carbohydrate (LF), LF with 850 mg theobromine (LF-TB) and high-fat/low-carbohydrate (HF) shakes.
| Nutrient | LF | LF-TB | HF |
|---|---|---|---|
| Energy (kcal) | 956 | 956 | 965 |
| Protein (g) | 19.4 | 19.4 | 17.9 |
| (E%)1 | 8 | 8 | 7 |
| Carbohydrates (g) | 193.7 | 193.7 | 85.7 |
| (E%) | 81 | 81 | 35 |
| Mono- and disaccharides (g) | 144.9 | 144.9 | 45.6 |
| Polysaccharides (g) | 48.8 | 48.8 | 40.1 |
| Total fat (g) | 10.5 | 10.5 | 60.6 |
| (E%) | 10 | 10 | 56 |
| Saturated fatty acids (g) | 3.2 | 3.2 | 36.0 |
| Monounsaturated fatty acids (g) | 4.0 | 4.0 | 18.7 |
| Polyunsaturated fatty acids (g) | 1.1 | 1.1 | 4.1 |
| Cholesterol (mg) | 334 | 334 | 341 |
| Theobromine (mg) | 0 | 850 | 0 |
1E%: energy percent.